FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2983410537> ?p ?o ?g. }

• W2983410537 endingPage "5423" @default.
• W2983410537 startingPage "5423" @default.
• W2983410537 abstract "Introduction. Myelodysplastic Syndrome (MDS) is a disease of the elderly. Apart from IPSS, IPSS-R and WPSS, several indexes incorporating patient comorbidities (such as the MDS CI index- Della Porta et al Haematologica 2011, the HCT-CI index - Sorror et al Blood 2005) and performance status (the GFM index- Itzykson et al Blood 2011) have been used to predict outcome in MDS patients treated with azacytidine (AZA). We sought to investigate the effect of comorbidities on the outcome after AZA in a large group of patients from the MDS registry of the Hellenic MDS Study Group. Methods. The present study has been conducted as a retrospective observational cohort one. It included high-risk MDS and low blast count AML patients treated with AZA from 26 centers in Greece from 2007 to 2018. T-test and ANOVA were used to compare scale variables between two or more groups respectively. Univariate analysis of nominal and scale survival data was performed using Kaplan-Meier survival curves and Cox regression respectively. All variables achieving p<0.05 at univariate analysis were considered eligible for multivariate analysis; the latter was based on Cox regression method. Results. We analyzed 536 consecutive patients. Patient characteristics are depicted in Table 1. The median follow-up period was 27.5±4.8 months. 371 patients received at least four cycles of AZA and 165 patients received less than 4 cycles of AZA. Patients who received ≥4 cycles of AZA did not differ from those who received <4 cycles regarding gender, age, estimated Glomerular Filtration Rate (eGFR), cardiovascular, renal, and tumor comorbidities. Significantly higher IPSS-R and GFM scores at baseline were found in the group of patients receiving < 4 cycles of AZA compared to patients who received ≥ 4 cycles of AZA (p=0.042 and 0.05 respectively), while transfusion dependence at baseline occurred more often in patients who received ≥ 4 cycles of AZA (p=0.039). To assess the prognostic significance of risk factors on leukemia free survival (LFS) and overall survival (OS), univariate and multivariate analysis for the whole population was performed, as well as a landmark analysis for patients who were treated with at least 4 cycles of AZA. ECOG performance status and the presence of peripheral blasts were independent prognostic factors for LFS and OS for the whole cohort analysis while response to AZA and the presence of peripheral blasts were independent prognosticators for LFS and OS in the landmark analysis. In addition, prior low dose cytarabine was an independent adverse prognostic factor for LFS in the landmark analysis. As regards comorbidities, neither of MDS-CI, HCT-CI and GFM systems independently predicted LFS or OS in either analysis, but eGFR with a cut-off of 45 ml/min was a strong and independent prognosticator for LFS and OS in both the standard and the landmark analysis. Kaplan-Meier survival curves regarding LFS and OS at AZA initiation and landmark analysis after 4th cycle of AZA in relation with eGFR are shown in Figure 1. Conclusion. This is the first study to demonstrate the importance of eGFR at baseline as a prognostic marker for LFS and OS in high-risk MDS and low-blast AML patients treated with AZA. The role of comorbidities and PS needs to be further evaluated in this patient group. Disclosures Symeonidis: Roche: Membership on an entity's Board of Directors or advisory committees, Research Funding; Sanofi: Research Funding; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Gilead: Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Membership on an entity's Board of Directors or advisory committees, Research Funding; MSD: Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding; Pfizer: Research Funding; Tekeda: Membership on an entity's Board of Directors or advisory committees, Research Funding. Vassilakopoulos:Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees; WinMedica: Honoraria, Membership on an entity's Board of Directors or advisory committees; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene / GenesisPharma: Honoraria, Membership on an entity's Board of Directors or advisory committees; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees. Panayiotidis:Bayer: Other: Support of clinical trial. Pappa:Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Research Funding; Gilead: Honoraria, Research Funding; Novartis: Honoraria, Research Funding, Speakers Bureau; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene / GenesisPharma: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Abbvie: Research Funding; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Kotsianidis:Celgene: Research Funding." @default.
• W2983410537 created "2019-11-22" @default.
• W2983410537 creator A5004716597 @default.
• W2983410537 creator A5016064577 @default.
• W2983410537 creator A5019954410 @default.
• W2983410537 creator A5024960041 @default.
• W2983410537 creator A5025768647 @default.
• W2983410537 creator A5028089840 @default.
• W2983410537 creator A5033498725 @default.
• W2983410537 creator A5033750115 @default.
• W2983410537 creator A5034834044 @default.
• W2983410537 creator A5036299617 @default.
• W2983410537 creator A5036771098 @default.
• W2983410537 creator A5039172241 @default.
• W2983410537 creator A5049817881 @default.
• W2983410537 creator A5052918575 @default.
• W2983410537 creator A5052953879 @default.
• W2983410537 creator A5056925580 @default.
• W2983410537 creator A5061193434 @default.
• W2983410537 creator A5065368922 @default.
• W2983410537 creator A5066480179 @default.
• W2983410537 creator A5068540445 @default.
• W2983410537 creator A5068927620 @default.
• W2983410537 creator A5069442236 @default.
• W2983410537 creator A5076779960 @default.
• W2983410537 creator A5080172626 @default.
• W2983410537 creator A5082219280 @default.
• W2983410537 creator A5083412701 @default.
• W2983410537 creator A5084504807 @default.
• W2983410537 date "2019-11-13" @default.
• W2983410537 modified "2023-10-17" @default.
• W2983410537 title "Estimated Glomerular Filtration Rate Is an Independent Predictor of Outcome in High-Risk Myelodysplastic Syndrome (MDS) and Low Blast Count Acute Myeloid Leukaemia (AML) Patients Treated with Azacytidine (AZA). a Retrospective Study from the MDS Registry of the Hellenic MDS Study Group" @default.
• W2983410537 doi "https://doi.org/10.1182/blood-2019-125806" @default.
• W2983410537 hasPublicationYear "2019" @default.
• W2983410537 type Work @default.
• W2983410537 sameAs 2983410537 @default.
• W2983410537 citedByCount "0" @default.
• W2983410537 crossrefType "journal-article" @default.
• W2983410537 hasAuthorship W2983410537A5004716597 @default.
• W2983410537 hasAuthorship W2983410537A5016064577 @default.
• W2983410537 hasAuthorship W2983410537A5019954410 @default.
• W2983410537 hasAuthorship W2983410537A5024960041 @default.
• W2983410537 hasAuthorship W2983410537A5025768647 @default.
• W2983410537 hasAuthorship W2983410537A5028089840 @default.
• W2983410537 hasAuthorship W2983410537A5033498725 @default.
• W2983410537 hasAuthorship W2983410537A5033750115 @default.
• W2983410537 hasAuthorship W2983410537A5034834044 @default.
• W2983410537 hasAuthorship W2983410537A5036299617 @default.
• W2983410537 hasAuthorship W2983410537A5036771098 @default.
• W2983410537 hasAuthorship W2983410537A5039172241 @default.
• W2983410537 hasAuthorship W2983410537A5049817881 @default.
• W2983410537 hasAuthorship W2983410537A5052918575 @default.
• W2983410537 hasAuthorship W2983410537A5052953879 @default.
• W2983410537 hasAuthorship W2983410537A5056925580 @default.
• W2983410537 hasAuthorship W2983410537A5061193434 @default.
• W2983410537 hasAuthorship W2983410537A5065368922 @default.
• W2983410537 hasAuthorship W2983410537A5066480179 @default.
• W2983410537 hasAuthorship W2983410537A5068540445 @default.
• W2983410537 hasAuthorship W2983410537A5068927620 @default.
• W2983410537 hasAuthorship W2983410537A5069442236 @default.
• W2983410537 hasAuthorship W2983410537A5076779960 @default.
• W2983410537 hasAuthorship W2983410537A5080172626 @default.
• W2983410537 hasAuthorship W2983410537A5082219280 @default.
• W2983410537 hasAuthorship W2983410537A5083412701 @default.
• W2983410537 hasAuthorship W2983410537A5084504807 @default.
• W2983410537 hasConcept C10515644 @default.
• W2983410537 hasConcept C126322002 @default.
• W2983410537 hasConcept C144301174 @default.
• W2983410537 hasConcept C159641895 @default.
• W2983410537 hasConcept C167135981 @default.
• W2983410537 hasConcept C2780007613 @default.
• W2983410537 hasConcept C2780240888 @default.
• W2983410537 hasConcept C2780817109 @default.
• W2983410537 hasConcept C38180746 @default.
• W2983410537 hasConcept C50382708 @default.
• W2983410537 hasConcept C71924100 @default.
• W2983410537 hasConceptScore W2983410537C10515644 @default.
• W2983410537 hasConceptScore W2983410537C126322002 @default.
• W2983410537 hasConceptScore W2983410537C144301174 @default.
• W2983410537 hasConceptScore W2983410537C159641895 @default.
• W2983410537 hasConceptScore W2983410537C167135981 @default.
• W2983410537 hasConceptScore W2983410537C2780007613 @default.
• W2983410537 hasConceptScore W2983410537C2780240888 @default.
• W2983410537 hasConceptScore W2983410537C2780817109 @default.
• W2983410537 hasConceptScore W2983410537C38180746 @default.
• W2983410537 hasConceptScore W2983410537C50382708 @default.
• W2983410537 hasConceptScore W2983410537C71924100 @default.
• W2983410537 hasIssue "Supplement_1" @default.
• W2983410537 hasLocation W29834105371 @default.
• W2983410537 hasOpenAccess W2983410537 @default.
• W2983410537 hasPrimaryLocation W29834105371 @default.
• W2983410537 hasRelatedWork W1973063050 @default.
• W2983410537 hasRelatedWork W1981978962 @default.
• W2983410537 hasRelatedWork W2016531290 @default.
• W2983410537 hasRelatedWork W2052032788 @default.
• W2983410537 hasRelatedWork W2067862448 @default.
• W2983410537 hasRelatedWork W2255342222 @default.
• W2983410537 hasRelatedWork W2889746435 @default.

• next